A Phase 2 interventional study of Elsubrutinib and Placebo for elsubrutinib in Systemic Lupus Erythematosus (SLE), sponsored by AbbVie. Completed at 160 sites in 21 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-07-21.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.
Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 63rd largest by enrollment of the 407 interventional ones that give a count, is one of 19 that started in 2019, is one of 120 in phase 2, and was the 293rd registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:
National Human Genome Research Institute (NHGRI) · Sites in United States, Peru
Ages 18–115
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
Stephan Grupp MD PhD · Sites in United States
Ages 8–25
EMD Serono Research & Development Institute, Inc. · Sites in United States
Ages 18–76
Fate Therapeutics · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
477 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 130 · Phase 2 151 · Phase 3 75 · Phase 4 17
First in 1986; this study’s year is marked. 19 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 341 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 70 across the 407 interventional studies, 223 across the 67 observational. Of the 309 that completed or were terminated, 147 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
264 of 477 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
AbbVie has 8 studies filed under Lupus Erythematosus, Systemic — fewer than ten, so there is no comparison to draw.
33 of the studies in Lupus Erythematosus, Systemic with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05672576Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus | 2026-12-31 |
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05843643Phase 3AbbVieProgram to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | 2027-03 |
| NCT05639114Phase 3Novartis PharmaceuticalsPhase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) | 2027-03-26 |
| NCT05648500Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | 2027-03-31 |
Add all 33 to your calendar (.ics) → With an account.
Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of this study was to evaluate the safety and efficacy of elsubrutinib, upadacitinib (UPA), and ABBV-599 (elsubrutinib/upadacitinib) High Dose and Low Dose combinations vs placebo for the treatment of signs and symptoms of Systemic Lupus Erythematosus (SLE) in participants with moderately to severely active SLE and to define doses for further development.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At Screening, must have at least one of the following:
SLEDAI-2K (SLE Disease Activity Index) ≥ 6 despite background therapy as reported and independently adjudicated (clinical score ≥ 4, excluding lupus headache and/or organic brain syndrome) at Screening:
Must be on background treatment, stable for 30 days prior to Baseline and throughout the study with antimalarial(s), prednisone (or prednisone equivalent) (≤ 20 mg), azathioprine (≤ 150 mg), mycophenolate (\<2 g), leflunomide (≤ 20 mg), cyclosporine, tacrolimus, and/or methotrexate (MTX) (≤ 20 mg).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo capsule for elsubrutinib once a day by mouth for up to 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for up to 48 weeks
Drug: Placebo for elsubrutinib · Drug: Placebo for upadacitinib
60 mg elsubrutinib capsule once a day by mouth for up to 48 weeks; 30 mg upadacitinib film-coated tablet once a day by mouth for up to 48 weeks
Drug: Elsubrutinib · Drug: Upadacitinib
Placebo capsule for elsubrutinib once a day by mouth for up to 48 weeks; 30 mg upadacitinib film-coated tablet once a day by mouth for up to 48 weeks
Drug: Placebo for elsubrutinib · Drug: Upadacitinib
60 mg elsubrutinib capsule once a day by mouth for up to 24 weeks; 15 mg upadacitinib film-coated tablet once a day by mouth for up to 24 weeks
Drug: Elsubrutinib · Drug: Upadacitinib
60 mg elsubrutinib capsule once a day by mouth for up to 24 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for up to 24 weeks
Drug: Elsubrutinib · Drug: Placebo for upadacitinib
Capsule; Oral
Also known as: ABBV-105
Capsule; Oral
Film-coated tablet; Oral
Also known as: RINVOQ
Film-coated tablet; Oral
Percentage of Participants Achieving SLE Responder Index (SRI)-4 and Steroid Dose ≤ 10 mg Prednisone Equivalent Once a Day (QD) at Week 24
SLE Responder Index (SRI)-4 is defined as follows with all criteria compared to Baseline: * ≥ 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score * No worsening of the overall condition (\< 0.3 point increase in Physician's Global Assessment \[PhGA\]) * No new British Isles Lupus Assessment Group (BILAG) A or more than 1 new BILAG B disease activity scores (i.e., no organ system changes from baseline B/C/D/E to A and no more than 1 organ system changes from baseline C/D/E to B). A letter score is assigned to each organ system with following indications: A = severe, B = moderate, C = mild, D = inactive with prior history, and E = inactive with no history.
Time frame: Baseline, Week 24
Percentage of Participants Achieving SLE Responder Index (SRI)-4 at Week 24
SLE Responder Index (SRI)-4 is defined as follows with all criteria compared to Baseline: * ≥ 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score * No worsening of the overall condition (\< 0.3 point increase in Physician's Global Assessment \[PhGA\]) * No new British Isles Lupus Assessment Group (BILAG) A or more than 1 new BILAG B disease activity scores (i.e., no organ system changes from baseline B/C/D/E to A and no more than 1 organ system changes from baseline C/D/E to B). A letter score is assigned to each organ system with following indications: A = severe, B = moderate, C = mild, D = inactive with prior history, and E = inactive with no history.
Time frame: Baseline, Week 24
Percentage of Participants Achieving British Isles Lupus Assessment Group (BILAG) Based Combined Lupus Assessment (BICLA) Response at Week 24
BICLA is a composite responder index. Achievement of BICLA response is defined as improvement in all initial A and B BILAG scores, with no more than one new BILAG B score without worsening of the overall condition (no worsening in Physician's Global Assessment \[PhGA\], \< 0.3 point increase) and no worsening of the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score.
Time frame: Baseline, Week 24
Percentage of Participants Achieving Lupus Low Disease Activity State (LLDAS) at Week 24
LLDAS is a state of low disease activity based on Systemic Lupus Erythematosus Disease Activity Index 2000 score (SLEDAI-2K score ≤4 excluding SLEDAI-2K activity in major organ systems), absence of SLE disease activity in major organ systems and new disease activity, Physician's Global Assessment (PhGA ≤1), and concomitant medication usage (steroid dose ≤7.5 mg QD and toleration of immunosuppressive drugs at standard maintenance doses).
Time frame: Baseline, Week 24
Change From Baseline in Daily Prednisone Dose at Week 24
Participants' current use of steroid therapy was assessed at each study visit, and the amount of daily prednisone was documented.
Time frame: From Baseline to Week 24
Number of Flares Per Patient-year by Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) SLEDAI Flare Index Through Week 24
The SELENA SLEDAI flare index defines mild/moderate or severe SLE flares using the SLEDAI score, definitions of worsening signs and symptoms, treatment changes, and Physician's Global Assessment of Disease Activity.
Time frame: From Baseline to Week 24
| Milestone | Elsubrutinib Placebo/Upadacitinib Placebo | ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) | Elsubrutinib Placebo/Upadacitinib 30 mg | ABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg) | Elsubrutinib 60 mg/Upadacitinib Placebo |
|---|---|---|---|---|---|
| Started | 75 | 68 | 62 | 69 | 67 |
| Completed | 52 | 52 | 51 | 24 | 29 |
| Not completed | 23 | 16 | 11 | 45 | 38 |
| Withdrew: Adverse event | 2 | 5 | 3 | 5 | 6 |
| Withdrew: Withdrawal by subject | 10 | 4 | 5 | 6 | 5 |
| Withdrew: Lost to follow-up | 2 | 2 | 2 | 0 | 1 |
| Withdrew: Covid-19 infection | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Other, not specified | 9 | 4 | 1 | 1 | 2 |
| Withdrew: Sponsor decision based on interim analysis data review | 0 | 0 | 0 | 33 | 24 |
SLE Responder Index (SRI)-4 is defined as follows with all criteria compared to Baseline: * ≥ 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score * No worsening of the overall condition (\< 0.3 point increase in Physician's Global Assessment \[PhGA\]) * No new British Isles Lupus Assessment Group (BILAG) A or more than 1 new BILAG B disease activity scores (i.e., no organ system changes from baseline B/C/D/E to A and no more than 1 organ system changes from baseline C/D/E to B). A letter score is assigned to each organ system with following indications: A = severe, B = moderate, C = mild, D = inactive with prior history, and E = inactive with no history.
| percentage of participants | Elsubrutinib Placebo/Upadacitinib Placebo | ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) | Elsubrutinib Placebo/Upadacitinib 30 mg |
|---|---|---|---|
| Percentage of Participants Achieving SLE Responder Index (SRI)-4 and Steroid Dose ≤ 10 mg Prednisone Equivalent Once a Day (QD) at Week 24 | 37.3 (26.4 to 48.3) | 48.5 (36.7 to 60.4) | 54.8 (42.5 to 67.2) |
SLE Responder Index (SRI)-4 is defined as follows with all criteria compared to Baseline: * ≥ 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score * No worsening of the overall condition (\< 0.3 point increase in Physician's Global Assessment \[PhGA\]) * No new British Isles Lupus Assessment Group (BILAG) A or more than 1 new BILAG B disease activity scores (i.e., no organ system changes from baseline B/C/D/E to A and no more than 1 organ system changes from baseline C/D/E to B). A letter score is assigned to each organ system with following indications: A = severe, B = moderate, C = mild, D = inactive with prior history, and E = inactive with no history.
| percentage of participants | Elsubrutinib Placebo/Upadacitinib Placebo | ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) | Elsubrutinib Placebo/Upadacitinib 30 mg |
|---|---|---|---|
| Percentage of Participants Achieving SLE Responder Index (SRI)-4 at Week 24 | 38.7 (27.6 to 49.7) | 54.4 (42.6 to 66.2) | 56.5 (44.1 to 68.8) |
BICLA is a composite responder index. Achievement of BICLA response is defined as improvement in all initial A and B BILAG scores, with no more than one new BILAG B score without worsening of the overall condition (no worsening in Physician's Global Assessment \[PhGA\], \< 0.3 point increase) and no worsening of the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score.
| percentage of participants | Elsubrutinib Placebo/Upadacitinib Placebo | ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) | Elsubrutinib Placebo/Upadacitinib 30 mg |
|---|---|---|---|
| Percentage of Participants Achieving British Isles Lupus Assessment Group (BILAG) Based Combined Lupus Assessment (BICLA) Response at Week 24 | 42.7 (31.5 to 53.9) | 54.4 (42.6 to 66.2) | 58.1 (45.8 to 70.3) |
LLDAS is a state of low disease activity based on Systemic Lupus Erythematosus Disease Activity Index 2000 score (SLEDAI-2K score ≤4 excluding SLEDAI-2K activity in major organ systems), absence of SLE disease activity in major organ systems and new disease activity, Physician's Global Assessment (PhGA ≤1), and concomitant medication usage (steroid dose ≤7.5 mg QD and toleration of immunosuppressive drugs at standard maintenance doses).
| percentage of participants | Elsubrutinib Placebo/Upadacitinib Placebo | ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) | Elsubrutinib Placebo/Upadacitinib 30 mg |
|---|---|---|---|
| Percentage of Participants Achieving Lupus Low Disease Activity State (LLDAS) at Week 24 | 13.3 (5.6 to 21.0) | 30.9 (19.9 to 41.9) | 45.2 (32.8 to 57.5) |
Participants' current use of steroid therapy was assessed at each study visit, and the amount of daily prednisone was documented.
| mg | Elsubrutinib Placebo/Upadacitinib Placebo | ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) | Elsubrutinib Placebo/Upadacitinib 30 mg |
|---|---|---|---|
| Change From Baseline in Daily Prednisone Dose at Week 24 | -0.65 (-1.57 to 0.28) | -0.45 (-1.38 to 0.48) | -0.62 (-1.60 to 0.36) |
The SELENA SLEDAI flare index defines mild/moderate or severe SLE flares using the SLEDAI score, definitions of worsening signs and symptoms, treatment changes, and Physician's Global Assessment of Disease Activity.
| Events per patient-year | Elsubrutinib Placebo/Upadacitinib Placebo | ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) | Elsubrutinib Placebo/Upadacitinib 30 mg |
|---|---|---|---|
| Mild/Moderate | 2.45 (1.92 to 2.99) | 1.39 (0.97 to 1.81) | 1.76 (1.28 to 2.25) |
| Severe | 0.36 (0.16 to 0.56) | 0.26 (0.08 to 0.44) | 0.10 (-0.01 to 0.22) |
| Overall | 2.81 (2.24 to 3.38) | 1.65 (1.20 to 2.10) | 1.87 (1.37 to 2.36) |
Collected over All-cause mortality is reported from enrollment to end of study; median time on follow-up was 337.0 days, 337.0 days, 338.5 days, 281.0 days, and 295.0 days for the placebo, ABBV-599 High Dose, upadacitinib, ABBV-599 Low Dose, and elsubrutinib groups, respectively.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Elsubrutinib Placebo/Upadacitinib Placebo | 0/75 (0%) | 13/75 (17.3%) | 39/75 (52%) |
| ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) | 2/68 (2.9%) | 7/68 (10.3%) | 38/68 (55.9%) |
| Elsubrutinib Placebo/Upadacitinib 30 mg | 0/62 (0%) | 13/62 (21%) | 35/62 (56.5%) |
| ABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg) | 0/69 (0%) | 9/69 (13%) | 28/69 (40.6%) |
| Elsubrutinib 60 mg/Upadacitinib Placebo | 2/67 (3%) | 7/67 (10.4%) | 36/67 (53.7%) |
| Event | Elsubrutinib Placebo/Upadacitinib Placebo | ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) | Elsubrutinib Placebo/Upadacitinib 30 mg | ABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg) | Elsubrutinib 60 mg/Upadacitinib Placebo |
|---|---|---|---|---|---|
| PNEUMONIAInfections and infestations | 0/75 | 0/68 | 2/62 | 1/69 | 0/67 |
| SYSTEMIC LUPUS ERYTHEMATOSUSMusculoskeletal and connective tissue disorders | 1/75 | 1/68 | 1/62 | 2/69 | 1/67 |
| URETEROLITHIASISRenal and urinary disorders | 2/75 | 0/68 | 0/62 | 0/69 | 0/67 |
| ABORTION INDUCEDSurgical and medical procedures | 2/75 | 0/68 | 0/62 | 0/69 | 0/67 |
| STRESS CARDIOMYOPATHYCardiac disorders | 0/75 | 0/68 | 1/62 | 0/69 | 0/67 |
| COVID-19 PNEUMONIAInfections and infestations | 0/75 | 1/68 | 1/62 | 0/69 | 0/67 |
| DISSEMINATED VARICELLA ZOSTER VIRUS INFECTIONInfections and infestations | 0/75 | 0/68 | 1/62 | 0/69 | 0/67 |
| GASTROENTERITISInfections and infestations | 0/75 | 0/68 | 1/62 | 0/69 | 0/67 |
| GASTROENTERITIS VIRALInfections and infestations | 0/75 | 0/68 | 1/62 | 0/69 | 0/67 |
| PNEUMOCYSTIS JIROVECII PNEUMONIAInfections and infestations | 0/75 | 0/68 | 1/62 | 0/69 | 0/67 |
| Event | Elsubrutinib Placebo/Upadacitinib Placebo | ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) | Elsubrutinib Placebo/Upadacitinib 30 mg | ABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg) | Elsubrutinib 60 mg/Upadacitinib Placebo |
|---|---|---|---|---|---|
| URINARY TRACT INFECTIONInfections and infestations | 9/75 | 8/68 | 11/62 | 5/69 | 4/67 |
| HEADACHENervous system disorders | 9/75 | 4/68 | 2/62 | 7/69 | 10/67 |
| COVID-19Infections and infestations | 8/75 | 3/68 | 7/62 | 2/69 | 8/67 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 8/75 | 7/68 | 5/62 | 5/69 | 5/67 |
| HERPES ZOSTERInfections and infestations | 3/75 | 7/68 | 3/62 | 3/69 | 1/67 |
| NAUSEAGastrointestinal disorders | 6/75 | 4/68 | 4/62 | 2/69 | 6/67 |
| NASOPHARYNGITISInfections and infestations | 3/75 | 6/68 | 1/62 | 5/69 | 0/67 |
| DIARRHOEAGastrointestinal disorders | 6/75 | 3/68 | 4/62 | 3/69 | 2/67 |
| PYREXIAGeneral disorders | 6/75 | 3/68 | 3/62 | 2/69 | 1/67 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 5/75 | 3/68 | 1/62 | 2/69 | 5/67 |
Full Analysis Set: all randomized participants who received at least 1 dose of study drug
| Age, Continuous(years) | Elsubrutinib Placebo/Upadacitinib Placebo | ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) | Elsubrutinib Placebo/Upadacitinib 30 mg | ABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg) | Elsubrutinib 60 mg/Upadacitinib Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 41.7 ± 12.05 | 42.7 ± 11.27 | 42.5 ± 11.89 | 41.4 ± 11.85 | 42.0 ± 11.84 | 42.1 ± 11.73 |
| Sex: Female, Male(Participants) | Elsubrutinib Placebo/Upadacitinib Placebo | ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) | Elsubrutinib Placebo/Upadacitinib 30 mg | ABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg) | Elsubrutinib 60 mg/Upadacitinib Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 75 | 62 | 57 | 63 | 62 | 319 |
| Male | 0 | 6 | 5 | 6 | 5 | 22 |
| Race (NIH/OMB)(Participants) | Elsubrutinib Placebo/Upadacitinib Placebo | ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) | Elsubrutinib Placebo/Upadacitinib 30 mg | ABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg) | Elsubrutinib 60 mg/Upadacitinib Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 3 | 3 | 0 | 1 | 4 | 11 |
| Asian | 23 | 14 | 13 | 13 | 9 | 72 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 4 | 9 | 8 | 6 | 31 |
| White | 43 | 45 | 34 | 45 | 44 | 211 |
| More than one race | 2 | 2 | 6 | 2 | 4 | 16 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score(units on a scale) | Elsubrutinib Placebo/Upadacitinib Placebo | ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) | Elsubrutinib Placebo/Upadacitinib 30 mg | ABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg) | Elsubrutinib 60 mg/Upadacitinib Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 9.1 ± 3.88 | 8.9 ± 2.75 | 9.0 ± 2.75 | 8.8 ± 2.86 | 9.2 ± 3.18 | 9.0 ± 3.12 |
| Physician's Global Assessment (PhGA) score(units on a scale) | Elsubrutinib Placebo/Upadacitinib Placebo | ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) | Elsubrutinib Placebo/Upadacitinib 30 mg | ABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg) | Elsubrutinib 60 mg/Upadacitinib Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 1.75 ± 0.440 | 1.80 ± 0.417 | 1.70 ± 0.438 | 1.77 ± 0.422 | 1.77 ± 0.392 | 1.76 ± 0.421 |
| Daily dose of corticosteroid(mg/day) | Elsubrutinib Placebo/Upadacitinib Placebo | ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) | Elsubrutinib Placebo/Upadacitinib 30 mg | ABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg) | Elsubrutinib 60 mg/Upadacitinib Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 7.937 ± 7.1270 | 6.743 ± 6.3736 | 6.242 ± 6.0920 | 6.891 ± 6.1056 | 6.291 ± 6.1096 | 6.856 ± 6.3885 |
Showing the first 100 of 160 sites across 21 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Jul 2019 to primary completion in Jan 2022, 29 months.
Results were first posted in Jul 2023, 1 year 6 months after primary completion. A results delay was requested in Dec 2022.
Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 29 months is close to that.
Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elsubrutinib · Upadacitinib
Lupus Erythematosus, Systemic →